Abstract Background Testing of factor Xa inhibitors for the prevention of cardiovascular
events in patients with rheumatic heart disease–associated atrial fibrillation has been …

Background: In the Japanese Rivaroxaban Once-daily oral direct factor Xa inhibition
Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial …

Background Rivaroxaban has become an alternative to vitamin-K antagonists (VKA) for
stroke prevention in non-valvular atrial fibrillation (AF) patients due to its favourable risk …

Aim: To evaluate the efficacy, safety and tolerability of rivaroxaban for the secondary
prevention of stroke in patients with atrial fibrillation in clinical practice. Methods: Patients …

Atrial fibrillation (AF), the most common form of cardiac arrhythmia, is a major risk factor for
cardioembolic stroke. Dose-adjusted warfarin has been the gold standard for stroke …

Atrial fibrillation (AF) is associated with a fivefold increase in the risk of stroke. The Phase III
ROCKET AF (Rivaroxaban Once-Daily Oral Direct Factor Xa Inhibition Compared with …

Background: Gastrointestinal (GI) bleeding is a common complication of oral
anticoagulation. Objectives: This study evaluated GI bleeding in patients who received at …

Background: Although randomized trials demonstrate the noninferiority of rivaroxaban
compared with warfarin in the context of nonvalvular atrial fibrillation (AF), little is known …

Summary Background In ROCKET AF, rivaroxaban was non-inferior to adjusted-dose
warfarin in preventing stroke or systemic embolism among patients with atrial fibrillation …

Background: It is important to understand the risk of thromboembolism and bleeding in
patients with nonvalvular atrial fibrillation (NVAF) receiving direct oral anticoagulants; …